Follow us:Follow Us on Twitter Like Us on Facebook Follow Us on Google+ Watch videos on our Youtube channel
Most of medicine, as practiced today, can be traced back to the advances made since the 1940s. The development of antibiotics, a vaccine for polio, organ transplants, insulin, and CT and MRI scans have radically improved the ability of medicine to impact human disease. We are now on the verge of a medical revolution. The human genome, the 100,000 genes encoded by 3 billion chemical pairs in our DNA, has been decoded, opening up exciting, new opportunities for innovative treatments. Breakthroughs like this are providing us with unparalleled opportunities to develop effective treatments for cancer and many other diseases. Recent discoveries by scientists at the Maxine Dunitz Neurosurgical Institute have generated excitement and hope for control of diseases that can devastate the body's most vital organ - the brain.
It is estimated that one out of three people will be diagnosed with cancer in their lifetime. About 500,000 people die from cancer in the United States each year. For reasons that remain unexplained, even when analysis corrects for an aging population and improved diagnostic ability, the incidence of brain tumors continues to increase. More alarming is the rise in brain tumors in children. Brain tumors are now the leading cause of death from cancer in children. At the Maxine Dunitz Neurosurgical Institute (MDNSI), major clinical and research efforts are underway to develop an effective treatment for brain tumors. Important advances have already been made and novel clinical protocols are in progress. However, we plan to expand our research efforts to accelerate the discoveries from our laboratories and the translation of these discoveries to new treatments.
Listed below are links to our Basic Science Research Studies. To learn more about our Brain Tumor and Neurovascular Patient Clinical Trials, please click here.
- Age-sensitive Immunity in Brain Cancer and Neurodegenerative Disease, Principal Investigator, Christopher Wheeler, PhD
- Breaking the Blood-Brain Tumor Barrier, Principal Investigator, Keith L. Black, MD
- Dendritic Cell Vaccination for Malignant Gliomas, Principal Investigator, John S. Yu, MD
- Gene Therapy Strategies, Principal Investigator, John S. Yu, MD
- Molecular Oncology, Principal Investigator, Julia Ljubimova, MD, PhD
- Nanomedicine Treatment for Brain Tumors, Principal Investigator, Julia Ljubimova, MD, PhD
- Neural Stem Cells for Cancer and Neurodegenerative Diseases, Principal Investigator, John S. Yu, MD
- Neural Stem Cells for Parkinson's, Principal Investigator, Dwain Morris-Irvin, PhD, MPH
- Neuroimmunology of Degenerative Diseases, Principal Investigator, Terrence Town, PhD
The MDNSI also works closely with biophotonics researchers at Cedars-Sinai Medical Center, developing more effective methods to diagnose and demarcate tumors and to prevent stroke. For more information, please visit Cedars-Sinai's Biophotonics Research and Technology Development website.
Please visit Clinical Trials for more information about brain tumor patient clinical trials.
For an appointment, a second opinion or more information, please call 1-800-CEDARS-1 (1-800-233-2771) or e-mail us.